XORTX plans Q4 2026 FDA IND filing for XRx-026 gout trial using XORLO, targets USD 700 million U.S. market
XRTX•Study and commercialization timeline
The planned XRX-OXY-102 study aims to support a future NDA by clarifying dosing behavior and clinical benefit.
Management targets an NDA filing about one year after completing the study, subject to funding and execution.
The company pegged the U.S. gout opportunity at more than USD 700 million in annual market potential.
Planned FDA filing and program update
XORTX outlined plans to submit an FDA IND in Q4 2026 for its XRx-026 gout program using XORLO.
No new trial results were presented; the program is being advanced based on supportive prior results and FDA discussions.
